The Australian biotech giant has agreed to cut US drug prices and proceed with a $US1.5bn manufacturing expansion in a deal it says provides greater certainty over its exposure to US tariffs.
The Australian biotech giant has agreed to cut US drug prices and proceed with a $US1.5bn manufacturing expansion in a deal it says provides greater certainty over its exposure to US tariffs.
This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.